



Product Pipeline

With the recent FDA approval of KETARx™ for surgical pain management (anesthesia and sedation for surgical and diagnostic procedures), PharmaTher is executing a progressive plan to establish category leadership in the U.S. while advancing additional indications via the efficient 505(b)(2) pathway—particularly in rare disorders, where orphan-drug incentives and real-world evidence (RWE) can accelerate timelines.

KETARx™ Strategic Plan

With KETARx™ now FDA Approved, we are advancing an ambitious 'capital-efficient' commercial & regulatory initiative to unlock new indications and opportunities

Commercialization in growing surgical and diagnostic procedural uses



505(b)(2) "literature-based" NDA strategy for rare and ultra-rare disorders

PHARMATHER

OTCQB: PHRRF | CSE: PHRM

KETARx™ Ketamine Portfolio

Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Approval
Pain and Surgery Management					
Complex Regional Pain Syndrome	Published & Exclusive Access to RWE & RCTs Data to Support NDA via 505(b)(2)				
Undisclosed Rare disorder	Published & Exclusive Access to RWE & RCTs Data to Support NDA via 505(b)(2)				
Parkinson's Disease	Adaptive Phase 3 ready. Seeking Pharm Partner			Patent No. 12,128,012, expiring May 14, 2041	
ALS	Phase 1/2 ready. Grant funding.			Patent No. 11,426,366, expiring May 5, 2036	
	Current	12-18 Months			


RWE: Real-world Evidence
RCTs - Randomized Clinical Trials

PHARMATHER

OTCQB: PHRRF | CSE: PHRM



KETARx™ Growth Pathway



KETARx™ Opportunities

Seeking Pharma Partnerships

Adaptive Phase 3 study



Parkinson's Disease
(Levodopa-induced dyskinesia)

Microneedle Hydrogel Patch



Novel delivery technologies administering Ketamine for
hospital, clinic and home use

Sub-Q On-Body Pump



PHARMATHER

OTCQB: PHRRF | CSE: PHRM

Connect With Us



PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario Canada
M5C 1P1



© COPYRIGHT 2025. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.